title: In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin.
abstract: A large number of multidrug resistance (MDR) modulators, termed chemosensitizers, have been identified from a variety of chemicals, but most have been proven to be clinically toxic. Low concentrations of the pleuromutilin-derived semi-synthetic antibiotic tiamulin (0.1 to 10 microM) sensitized the three highly resistant P-glycoprotein (Pgp)-overexpressing tumor cell lines P388 (murine lymphoid leukemia), AS30-D (rat hepatoma), CEM (human lymphoblastic leukemia), and the barely resistant AS30-D/S cell lines to several MDR-related anticancer drugs. Flow cytometric analysis showed that tiamulin significantly increased the intracellular accumulation of daunomycin. When compared to reference modulating agents such as verapamil and cyclosporin A, tiamulin proved to be 1.1 to 8.3 times more efficient in sensitizing the resistant cell lines. Moreover, when given i.p. (1.6 microg/mg body weight), tiamulin increased the survival rate of adriamycin-treated mice bearing the P388/ADR25 tumor line by 29%. In the presence of an anticancer drug, tiamulin inhibited both ATPase and drug transport activities of Pgp in plasma membranes from tumor cells. Tiamulin is thus a potent chemosensitizer that antagonizes the Pgp-mediated chemoresistance in many tumor cell lines expressing the MDR phenotype at different levels and displays no toxic effects on contractile tissues at active doses, therefore providing the promise for potential clinical applications.
authors.affiliation: Institut de Biologie et Chimie des Proteines, UPR 412 CNRS, Lyon, France. lg.baggetto@ibcp.fr
authors.forename: L G
authors.initials: LG
authors.lastname: Baggetto
authors.forename: M
authors.initials: M
authors.lastname: Dong
authors.forename: J
authors.initials: J
authors.lastname: Bernaud
authors.forename: L
authors.initials: L
authors.lastname: Espinosa
authors.forename: D
authors.initials: D
authors.lastname: Rigal
authors.forename: R
authors.initials: R
authors.lastname: Bonvallet
authors.forename: E
authors.initials: E
authors.lastname: Marthinet
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects; D003630:Daunorubicin / Q000493:pharmacokinetics; D004224:Diterpenes / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D051381:Rats; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000493:pharmacokinetics
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D015220:Calcium Channels; D004224:Diterpenes; D014747:Vinblastine; C014224:tiamulin; D000251:Adenosine Triphosphatases; D003630:Daunorubicin